Cancer and Kinases: Lessons from the Clinic Organizer(s): Brian J. Druker, Charles L. Sawyers and Kenneth W. Bair Date: February 14 - 19, 2006
Location: Eldorado Hotel & Spa, Santa Fe, NM, USAKinases are one of the most commonly mutated genes in cancer and numerous inhibitors of kinases involved in cancer are being tested in the clinic and many others are in development. Some such as imatinib (Gleevec) have been remarkably successful, while others have been much less successful. In addition, there have been significant improvements in the ability to synthesize specific kinase inhibitors. However, there remains a major need to understand the structural basis of compound selectivity, prospectively identify patients likely to respond to a kinase inhibitor, design improved pharmacodynamic endpoints, and understand the molecular basis of resistance to kinase inhibitor therapy. The goal of this meeting is to review the lessons learned from the successes and failures in the development and clinical application of kinase inhibitors to assist in more effective development and implementation of kinase inhibitors as therapeutic agents. Scholarship Deadline: October 13 2005 Discounted Abstract Deadline: October 13 2005 Abstract Deadline: November 7 2005 Discounted Registration Deadline: December 14 2005 We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Ambit Biosciences, Inc.
Cell Signaling Technology, Inc.
Chiron Corporation
Exelixis, Inc.
SGX Pharmaceuticals
|